Table 1.
Demographic and clinical manifestations of SLE patients at enrollment visit
| Number of Patients | 1206 | |
| Gender, n, (%) | Female | 1080 (89.6) |
| Male | 126 (10.5) | |
| Age (years) (mean ± SD) at enrollment | 34.5 ± 13.2 | |
| Ethnicity, % | Caucasian | 47.4 |
| Hispanic | 16.5 | |
| Asian | 16.5 | |
| Black | 15.6 | |
| Other | 3.9 | |
| Region, % | Canada | 22.2 |
| US, Mexico | 41.4 | |
| Europe | 25.1 | |
| Asia | 11.3 | |
| Single/Married/Other, % | 46.6/40.8/12.6 | |
| Post secondary education, % | 62.1 | |
| Disease duration (months) (mean ± SD) | 5.4 ± 4.2 | |
| Number of ACR criteria (mean ± SD) | 4.5 ±1.01 | |
| Cumulative ACR manifestations, n, % | ||
| Malar rash | 501 (41.5) | |
| Discoid rash | 174 (14.4) | |
| Photosensitivity | 434 (35.9) | |
| Oral/nasopharyngeal ulcers | 539 (44.7) | |
| Serositis | 336 (27.8) | |
| Arthritis | 886 (73.5) | |
| Renal disorder | 346 (28.7) | |
| Neurological disorder | 71 (5.9) | |
| Hematologic disorder | 742 (61.5) | |
| Immunologic disorder | 923 (76.5) | |
| Antinuclear antibody | 1158 (96.0) | |
| SLEDAI score (mean ± SD) | 5.4 ± 5.5 | |
| SLICC/ACR score (mean ± SD) | 0.3 ± 0.8 | |
| Medications, % | ||
| Corticosteroids | 835 (69.2) | |
| Antimalarials | 744 (61.7) | |
| Immunosuppressants | 471 (39.1) | |
| Aspirin | 170 (14.1) | |
| Antidepressants | 105 (8.7) | |
| Anticonvulsants | 48 (3.9) | |
| Warfarin | 59 (4.9) | |
| Antipsychotics | 7 (0.6) | |